Current Infectious Disease Reports

, Volume 15, Issue 3, pp 251–262 | Cite as

Probiotics and Prebiotics in Infants and Children

  • Y. Vandenplas
  • E. De Greef
  • T. Devreker
  • G. Veereman-Wauters
  • B. Hauser
Pediatric Infectious Diseases (I Brook, Section Editor)


Probiotics and prebiotics have a major influence on gastrointestinal flora composition. This review analyses the relationship between this change in flora composition and health benefits in children. Literature databases were searched for relevant articles. Despite exhaustive research on the subject in different indications, such as prevention and treatment of acute gastroenteritis, antibiotic associated diarrhea (AAD), traveler's diarrhea, inflammatory bowel disease, irritable bowel syndrome, Helicobacter pylori, necrotizing enterocolitis, constipation, allergy and atopic dermatitis, colic and extraintestinal infections, reports of clear benefits for the use of prebiotics and probiotics in pediatric disorders remain scarce. The best evidence has been provided for the use of probiotics in acute gastroenteritis and in prevention of AAD. However, AAD in children is in general mild, and only seldom necessitates additional interventions. Overall, the duration of acute infectious diarrhea is reduced by approximately 24 hours. Evidence for clinically relevant benefit in all other indications (inflammatory bowel disease, irritable bowel syndrome, constipation, allergy) is weak to nonexistent. Selected probiotic strains given during late pregnancy and early infancy decrease atopic dermatitis. Adverse effects have very seldom been reported. Since the risk seems minimal to nonexistent, prebiotics and probiotics may be helpful in the prevention and treatment of some disorders in children, although the evidence for benefit is limited. The best evidence has been accumulated for some lactobacilli strains and for Saccharomyces boulardii in the reduction of the duration of acute diarrhea due to gastroenteritis and prevention of AAD.


Probiotics Prebiotics Synbiotics Children Gastrointestinal flora Antibiotics Diarrhea 


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Johnson CL, Versalovic J. The human microbiome and its potential importance to pediatrics. Pediatrics. 2012;129:950–60.PubMedCrossRefGoogle Scholar
  2. 2.
    •• Reid G. Microbiology: Categorize probiotics to speed research. Nature. 2012;485:446. Classifies different probiotic products and proposes minimal requirements for claims.PubMedCrossRefGoogle Scholar
  3. 3.
    Ritchie ML, Romanuk TN. A meta-analysis of probiotic efficacy for gastrointestinal diseases. PLoS One. 2012;7:e34938.PubMedCrossRefGoogle Scholar
  4. 4.
    Vandenplas Y. Identification of probiotics by specific strain name. Aliment Pharmacol Ther. 2012;35:860.CrossRefGoogle Scholar
  5. 5.
    Bicer S, Sahin GT, Koncay B, et al. Incidence assessment of rotavirus and adenovirus associated acute gastroenteritis cases in early childhood. Infez Med. 2011;19:113–9.PubMedGoogle Scholar
  6. 6.
    Muhsen K, Shulman L, Rubinstein U, et al. TAU-HCLV Rota Study Group. Incidence, characteristics, and economic burden of rotavirus gastroenteritis associated with hospitalization of Israeli children <5 years of age, 2007–2008. J Infect Dis. 2009;200 Suppl 1:S254–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Goldman AS. Evolution of immune functions of the mammary gland and protection of the infant. Breastfeed Med. 2012;7:132–42.PubMedCrossRefGoogle Scholar
  8. 8.
    Martín V, Maldonado-Barragán A, Moles L, et al. Sharing of bacterial strains between breast milk and infant feces. J Hum Lact. 2012;28:36–44.PubMedCrossRefGoogle Scholar
  9. 9.
    Totten SM, Zivkovic AM, Wu S, et al. Comprehensive profiles of human milk oligosaccharides yield highly sensitive and specific markers for determining secretor status in lactating mothers. J Proteome Res. 2012;11:6124–33.PubMedGoogle Scholar
  10. 10.
    Agustina R, Kok FJ, van de Rest O, et al. Randomized trial of probiotics and calcium on diarrhea and respiratory tract infections in Indonesian children. Pediatrics. 2012;129:e1155–64.PubMedCrossRefGoogle Scholar
  11. 11.
    Guandalini S. Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol. 2011;45(Suppl):S149–53.PubMedCrossRefGoogle Scholar
  12. 12.
    Wanke M, Szajewska H. Lack of an effect of Lactobacillus reuteri DSM 17938 in preventing nosocomial diarrhea in children: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2012;161:40–3.PubMedCrossRefGoogle Scholar
  13. 13.
    Gil-Campos M, López MÁ, Rodriguez-Benítez MV, et al. Lactobacillus fermentum CECT 5716 is safe and well tolerated in infants of 1–6 months of age: a randomized controlled trial. Pharmacol Res. 2012;65:231–8.PubMedCrossRefGoogle Scholar
  14. 14.
    • Braegger C, Chmielewska A, Decsi T, et al. ESPGHAN Committee on Nutrition. Supplementation of infant formula with probiotics and/or prebiotics: a systematic review and comment by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2011;52:238–50. An ESPGHAN position paper on (the poor evidence of benefit of) pre- and probiotics added to infant formula.PubMedCrossRefGoogle Scholar
  15. 15.
    Thomas DW, Greer FR. Clinical report: probiotics and prebiotics in pediatrics. Pediatrics. 2010;126:1217–31.PubMedCrossRefGoogle Scholar
  16. 16.
    Bruzzese E, Volpicelli M, Squeglia V, et al. A formula containing galacto- and fructo-oligosaccharides prevents intestinal and extra-intestinal infections: an observational study. Clin Nutr. 2009;28:156–61.PubMedCrossRefGoogle Scholar
  17. 17.
    • Guarino A, Dupont C, Gorelov AV, et al. The management of acute diarrhea in children in developed and developing areas: from evidence base to clinical practice. Expert Opin Pharmacother. 2012;13:17–26. For the first time, the socio-economic impact of decreasing the duration of diarrhea with 24 hours is recognized as important.PubMedCrossRefGoogle Scholar
  18. 18.
    Francavilla R, Lionetti E, Castellaneta S, et al. Randomised clinical trial: Lactobacillus reuteri DSM 17938 vs. placebo in children with acute diarrhoea – a double-blind study. Aliment Pharmacol Ther. 2012;36:363–9.PubMedCrossRefGoogle Scholar
  19. 19.
    Sarker SA, Sultana S, Fuchs GJ, et al. Lactobacillus paracasei strain ST11 has no effect on rotavirus but ameliorates the outcome of nonrotavirus diarrhea in children from Bangladesh. Pediatrics. 2005;116:e221–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Muñoz JA, Chenoll E, Casinos B, et al. Novel probiotic Bifidobacterium longum subsp. infantis CECT 7210 strain active against rotavirus infections. Appl Environ Microbiol. 2011;77:8775–83.PubMedCrossRefGoogle Scholar
  21. 21.
    Riaz M, Alam S, Malik A, Ali SM. Efficacy and safety of Saccharomyces boulardii in acute childhood diarrhea: a double blind randomised controlled trial. Indian J Pediatr. 2012;79:478–82.PubMedCrossRefGoogle Scholar
  22. 22.
    Allen SJ, Martinez EG, Gregorio GV, Dans LF. Probiotics for treating acute infectious diarrhoea. Cochrane Database Syst Rev. 2010;11, CD003048.PubMedGoogle Scholar
  23. 23.
    Churgay CA, Aftab Z. Gastroenteritis in children: Part II. Prevention and management. Am Fam Physician. 2012;85:1066–70.PubMedGoogle Scholar
  24. 24.
    Vandenplas Y. De Hert S; Probiotical study group. Cost/benefit of synbiotics in acute infectious gastroenteritis: spend to save. Benef Microbes. 2012;3:189–94.PubMedCrossRefGoogle Scholar
  25. 25.
    Hoekstra JH, Szajewska H, Zikri MA, et al. Oral rehydration solution containing a mixture of non-digestible carbohydrates in the treatment of acute diarrhea: a multicenter randomized placebo controlled study on behalf of the ESPGHAN working group on intestinal infections. J Pediatr Gastroenterol Nutr. 2004;39:239–45.PubMedCrossRefGoogle Scholar
  26. 26.
    Passariello A, Terrin G, De Marco G, et al. Efficacy of a new hypotonic oral rehydration solution containing zinc and prebiotics in the treatment of childhood acute diarrhea: a randomized controlled trial. J Pediatr. 2011;158:288–92.PubMedCrossRefGoogle Scholar
  27. 27.
    Passariello A, Terrin G, Cecere G, et al. Randomised clinical trial: efficacy of a new synbiotic formulation containing Lactobacillus paracasei B21060 plus arabinogalactan and xilooligosaccharides in children with acute diarrhoea. Aliment Pharmacol Ther. 2012;35:782–8.PubMedCrossRefGoogle Scholar
  28. 28.
    Vandenplas Y. De Hert SG; PROBIOTICAL-study group. Randomised clinical trial: the synbiotic food supplement Probiotical vs. placebo for acute gastroenteritis in children. Aliment Pharmacol Ther. 2011;34:862–7.PubMedCrossRefGoogle Scholar
  29. 29.
    Pieścik-Lech M, Shamir R, Guarino A, Szajewska H. Review article: the management of acute gastroenteritis in children. Aliment Pharmacol Ther. 2013;37:289–303.PubMedCrossRefGoogle Scholar
  30. 30.
    Hempel S, Newberry SJ, Maher AR, et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307:1959–69.PubMedCrossRefGoogle Scholar
  31. 31.
    Videlock EJ, Cremonini F. Meta-analysis: probiotics in antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2012;35:1355–69.PubMedCrossRefGoogle Scholar
  32. 32.
    Sazawal S, Hiremath G, Dhingra U, et al. Efficacy of probiotics in prevention of acute diarrhoea: a meta-analysis of masked, randomised, placebo-controlled trials. Lancet Infect Dis. 2006;6:374–82.PubMedCrossRefGoogle Scholar
  33. 33.
    •• Johnston BC, Goldenberg JZ, Vandvik PO, et al. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;11:CD004827. An excellent meta-analysis showing efficacy of selected probiotic strains in the prevention of antibiotic-associated diarrhea.PubMedGoogle Scholar
  34. 34.
    Pozzoni P, Riva A, Bellatorre AG, et al. Saccharomyces boulardii for the prevention of antibiotic-associated diarrhea in adult hospitalized patients: a single-center, randomized, double-blind, placebo-controlled trial. Am J Gastroenterol. 2012;107:922–31.PubMedCrossRefGoogle Scholar
  35. 35.
    Friedman G. The role of probiotics in the prevention and treatment of antibiotic-associated diarrhea and Clostridium difficile colitis. Gastroenterol Clin North Am. 2012;41:763–79.PubMedCrossRefGoogle Scholar
  36. 36.
    Cremonini F, Videlock EJ. Probiotics are associated with a decreased risk of antibiotic-associated diarrhoea. Evid Based Med. 2013;18:71–2.PubMedCrossRefGoogle Scholar
  37. 37.
    ESPGHAN Working Group on Probiotics and Prebiotics, Szajewska H, Weizman Z, Abu-Zekry M, et al. Inulin and fructo-oligosaccharides for the prevention of antibiotic-associated diarrhea in children: report by the ESPGHAN Working Group on Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2012;54:828–9.PubMedCrossRefGoogle Scholar
  38. 38.
    •• Vanhee LM, Goemé F, Nelis HJ, Coenye T. Quality control of fifteen probiotic products containing Saccharomyces boulardii. J Appl Microbiol. 2010;109:1745–52. A nice study showing that what matters are commercial products, not strains. Clinical studies should be performed with the commercial product.PubMedGoogle Scholar
  39. 39.
    McFarland LV. Probiotics and diarrhea. Ann Nutr Metab. 2010;57(Suppl):10–1.PubMedCrossRefGoogle Scholar
  40. 40.
    DuPont HL, Ericsson CD, Farthing MJ, et al. Expert review of the evidence base for prevention of travelers' diarrhea. J Travel Med. 2009;16:149–60.PubMedCrossRefGoogle Scholar
  41. 41.
    Kollaritsch H, Paulke-Korinek M, Wiedermann U. Traveler's diarrhea. Infect Dis Clin North Am. 2012;26:691–706.PubMedCrossRefGoogle Scholar
  42. 42.
    Oliva S, Di Nardo G, Ferrari F, et al. Randomised clinical trial: the effectiveness of Lactobacillus reuteri ATCC 55730 rectal enema in children with active distal ulcerative colitis. Aliment Pharmacol Ther. 2012;35:327–34.PubMedCrossRefGoogle Scholar
  43. 43.
    Miele E, Pascarella F, Giannetti E, et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol. 2009;104:437–43.PubMedCrossRefGoogle Scholar
  44. 44.
    Whelan K, Quigley EM. Probiotics in the management of irritable bowel syndrome and inflammatory bowel disease. Curr Opin Gastroenterol. 2013;29:184–9.PubMedCrossRefGoogle Scholar
  45. 45.
    Jonkers D, Penders J, Masclee A, Pierik M. Probiotics in the management of inflammatory bowel disease: a systematic review of intervention studies in adult patients. Drugs. 2012;72:803–23.PubMedCrossRefGoogle Scholar
  46. 46.
    • Fedorak R, Demeria D. Probiotic bacteria in the prevention and the treatment of inflammatory bowel disease. Gastroenterol Clin North Am. 2012;41:821–42. Although relating mainly to adults, this overview shows the (lack of ) evidence of probiotics in inflammatory bowel disease.PubMedCrossRefGoogle Scholar
  47. 47.
    Park KT, Perez F, Tsai R, et al. Cost-effectiveness analysis of adjunct VSL#3 therapy versus standard medical therapy in pediatric ulcerative colitis. J Pediatr Gastroenterol Nutr. 2011;53:489–96.PubMedGoogle Scholar
  48. 48.
    Huertas-Ceballos AA, Logan S, Bennett C, Macarthur C. Dietary interventions for recurrent abdominal pain (RAP) and irritable bowel syndrome (IBS) in childhood. Cochrane Database Syst Rev. 2009;1, CD003019.PubMedGoogle Scholar
  49. 49.
    Francavilla R, Miniello V, Magistà AM, et al. A randomized controlled trial of Lactobacillus GG in children with functional abdominal pain. Pediatrics. 2010;126:e1445–52.PubMedCrossRefGoogle Scholar
  50. 50.
    Horvath A, Dziechciarz P, Szajewska H. Meta-analysis: Lactobacillus rhamnosus GG for abdominal pain-related functional gastrointestinal disorders in childhood. Aliment Pharmacol Ther. 2011;33:1302–10.PubMedCrossRefGoogle Scholar
  51. 51.
    Vivatvakin B, Mahayosnond A, Theamboonlers A, et al. Effect of a whey-predominant starter formula containing LCPUFAs and oligosaccharides (FOS/GOS) on gastrointestinal comfort in infants. Asia Pac J Clin Nutr. 2010;19:473–80.PubMedGoogle Scholar
  52. 52.
    Khoshoo V, Sun SS, Storm H. Tolerance of an enteral formula with insoluble and prebiotic fiber in children with compromised gastrointestinal function. J Am Diet Assoc. 2010;110:1728–33.PubMedCrossRefGoogle Scholar
  53. 53.
    Lionetti E, Indrio F, Pavone L, et al. Role of probiotics in pediatric patients with Helicobacter pylori infection: a comprehensive review of the literature. Helicobacter. 2010;15:79–87.PubMedCrossRefGoogle Scholar
  54. 54.
    Kindermann A, Lopes AI. Helicobacter pylori infection in pediatrics. Helicobacter. 2009;14 Suppl 1:52–7.PubMedCrossRefGoogle Scholar
  55. 55.
    Lionetti E, Francavilla R, Castellazzi AM, et al. Probiotics and helicobacter pylori infection in children. J Biol Regul Homeost Agents. 2012;26(1 Suppl):69–76.Google Scholar
  56. 56.
    Lin WH, Lin CK, Sheu SJ, et al. Antagonistic activity of spent culture supernatants of lactic acid bacteria against Helicobacter pylori growth and infection in human gastric epithelial AGS cells. J Food Sci. 2009;74:225–30.CrossRefGoogle Scholar
  57. 57.
    Yang YJ, Sheu BS. Probiotics-containing yogurts suppress Helicobacter pylori load and modify immune response and intestinal microbiota in the Helicobacter pylori-infected children. Helicobacter. 2012;17:297–304.PubMedCrossRefGoogle Scholar
  58. 58.
    Szajewska H, Horvath A, Piwowarczyk A. Meta-analysis: the effects of Saccharomyces boulardii supplementation on Helicobacter pylori eradication rates and side effects during treatment. Aliment Pharmacol Ther. 2010;32:1069–79.PubMedCrossRefGoogle Scholar
  59. 59.
    • Malfertheiner P, Selgrad M, Bornschein J. Helicobacter pylori: clinical management. Curr Opin Gastroenterol. 2012;28:608–14. Many probiotics increase the eradication efficacy of standard treatment by about 10 %.PubMedCrossRefGoogle Scholar
  60. 60.
    Wilhelm SM, Johnson JL, Kale-Pradhan PB. Treating bugs with bugs: the role of probiotics as adjunctive therapy for Helicobacter pylori. Ann Pharmacother. 2011;45:960–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Hoyos AB. Reduced incidence of necrotizing enterocolitis associated with enteral administration of Lactobacillus acidophilus and Bifidobacterium infantis to neonates in an intensive care unit. Int J Infect Dis. 1999;3:197–202.PubMedCrossRefGoogle Scholar
  62. 62.
    Alfaleh K, Anabrees J, Bassler D, Al-Kharfi T. Probiotics for prevention of necrotizing enterocolitis in preterm infants. Cochrane Database Syst Rev. 2011;3, CD005496.PubMedGoogle Scholar
  63. 63.
    Downard CD, Renaud E, St Peter SD, et al. 2012 American Pediatric Surgical Association Outcomes Clinical Trials Committee. Treatment of necrotizing enterocolitis: an American Pediatric Surgical Association Outcomes and Clinical Trials Committee systematic review. J Pediatr Surg. 2012;47:2111–22.PubMedCrossRefGoogle Scholar
  64. 64.
    •• Mihatsch WA, Braegger CP, Decsi T, et al. Critical systematic review of the level of evidence for routine use of probiotics for reduction of mortality and prevention of necrotizing enterocolitis and sepsis in preterm infants. Clin Nutr. 2012;31:6–15. The efficacy of probiotics on the prevention of NEC is put in its right perspective.PubMedCrossRefGoogle Scholar
  65. 65.
    •• Janvier A, Lantos J, Barrington K. The politics of probiotics: probiotics, necrotizing enterocolitis, and the ethics of neonatal research. Acta Paediatr. 2013;102:116–8. These authors have a different opinion from Mihatsch et al. The debate "probiotic or not" in the prevention of necrotizing enterocolitis is open.PubMedCrossRefGoogle Scholar
  66. 66.
    Szajewska H. Probiotics and prebiotics in preterm infants: where are we? Where are we going? Early Hum Dev. 2010;86 Suppl 1:81–6.PubMedCrossRefGoogle Scholar
  67. 67.
    Tabbers MM, de Milliano I, Roseboom MG, Benninga MA. Is Bifidobacterium breve effective in the treatment of childhood constipation? Results from a pilot study. Nutr J. 2011;10:19.PubMedCrossRefGoogle Scholar
  68. 68.
    Coccorullo P, Strisciuglio C, Martinelli M, et al. Lactobacillus reuteri (DSM 17938) in infants with functional chronic constipation: a double-blind, randomized, placebo-controlled study. J Pediatr. 2010;157:598–602.PubMedCrossRefGoogle Scholar
  69. 69.
    Guerra PV, Lima LN, Souza TC, et al. Pediatric functional constipation treatment with Bifidobacterium-containing yogurt: a crossover, double-blind, controlled trial. World J Gastroenterol. 2011;17:3916–21.PubMedCrossRefGoogle Scholar
  70. 70.
    Tabbers MM, Chmielewska A, Roseboom MG, et al. Fermented milk containing Bifidobacterium lactis DN-173 010 in childhood constipation: a randomized, double-blind, controlled trial. Pediatrics. 2011;127:e1392–9.PubMedCrossRefGoogle Scholar
  71. 71.
    Tabbers MM, Boluyt N, Berger MY, Benninga MA. Nonpharmacologic treatments for childhood constipation: systematic review. Pediatrics. 2011;128:753–61.PubMedCrossRefGoogle Scholar
  72. 72.
    Schouten B, Van Esch BC, Kormelink TG, et al. Non-digestible oligosaccharides reduce immunoglobulin free light-chain concentrations in infants at risk for allergy. Pediatr Allergy Immunol. 2011;22:537–42.PubMedCrossRefGoogle Scholar
  73. 73.
    Osborn DA, Sinn JK. Probiotics in infants for prevention of allergic disease and food hypersensitivity. Cochrane Database Syst Rev. 2007;4:CD006475.PubMedGoogle Scholar
  74. 74.
    Dotterud CK, Storrø O, Johnsen R, Oien T. Probiotics in pregnant women to prevent allergic disease: a randomized, double-blind trial. Br J Dermatol. 2010;163:616–23.PubMedCrossRefGoogle Scholar
  75. 75.
    •• Doege K, Grajecki D, Zyriax BC, et al. Impact of maternal supplementation with probiotics during pregnancy on atopic eczema in childhood – a meta-analysis. Br J Nutr. 2012;107:1–6. Probiotics during pregnancy and their efficacy on prevention of atopic dermatitis in the newborn.PubMedCrossRefGoogle Scholar
  76. 76.
    Wickens K, Black P, Stanley TV, et al. A protective effect of Lactobacillus rhamnosus HN001 against eczema in the first 2 years of life persists to age 4 years. Clin Exp Allergy. 2012;42:1071–9.PubMedCrossRefGoogle Scholar
  77. 77.
    Pelucchi C, Chatenoud L, Turati F, et al. Probiotics supplementation during pregnancy or infancy for the prevention of atopic dermatitis: a meta-analysis. Epidemiology. 2012;23:402–14.PubMedCrossRefGoogle Scholar
  78. 78.
    Williams HC, Grindlay DJ. What's new in atopic eczema? An analysis of systematic reviews published in 2007 and 2008. Part 2. Disease prevention and treatment. Clin Exp Dermatol. 2010;35:223–7.PubMedCrossRefGoogle Scholar
  79. 79.
    van der Aa LB, Lutter R, Heymans HS, et al. Synbad Study Group. No detectable beneficial systemic immunomodulatory effects of a specific synbiotic mixture in infants with atopic dermatitis. Clin Exp Allergy. 2012;42:531–9.PubMedCrossRefGoogle Scholar
  80. 80.
    van der Aa LB, van Aalderen WM, Heymans HS, et al. Synbad Study Group. Synbiotics prevent asthma-like symptoms in infants with atopic dermatitis. Allergy. 2011;66:170–7.PubMedCrossRefGoogle Scholar
  81. 81.
    Wu KG, Li TH, Peng HJ. Lactobacillus salivarius plus fructo-oligosaccharide is superior to fructo-oligosaccharide alone for treating children with moderate to severe atopic dermatitis: a double-blind, randomized, clinical trial of efficacy and safety. Br J Dermatol. 2012;166:129–36.PubMedCrossRefGoogle Scholar
  82. 82.
    Han Y, Kim B, Ban J, et al. A randomized trial of Lactobacillus plantarum CJLP133 for the treatment of atopic dermatitis. Pediatr Allergy Immunol. 2012;23:667–73.PubMedCrossRefGoogle Scholar
  83. 83.
    Gore C, Custovic A, Tannock GW, et al. Treatment and secondary prevention effects of the probiotics Lactobacillus paracasei or Bifidobacterium lactis on early infant eczema: randomized controlled trial with follow-up until age 3 years. Clin Exp Allergy. 2012;42:112–22.PubMedCrossRefGoogle Scholar
  84. 84.
    •• Bath-Hextall FJ, Jenkinson C, Humphreys R, Williams HC. Dietary supplements for established atopic eczema. Cochrane Database Syst Rev. 2012;2:CD005205. Probiotics during pregnancy and their efficacy on prevention of atopic dermatitis in the newborn.PubMedGoogle Scholar
  85. 85.
    Savino F, Cordisco L, Tarasco V, et al. Lactobacillus reuteri DSM 17938 in infantile colic: a randomized, double-blind, placebo-controlled trial. Pediatrics. 2010;126:e526–33.PubMedCrossRefGoogle Scholar
  86. 86.
    Szajewska H, Gyrczuk E, Horvath A. Lactobacillus reuteri DSM 17938 for the management of infantile colic in breastfed infants: a randomized, double-blind, placebo-controlled trial. J Pediatr. 2013;162:257–62.PubMedCrossRefGoogle Scholar
  87. 87.
    Dupont C, Rivero M, Grillon C, et al. Alpha-lactalbumin-enriched and probiotic-supplemented infant formula in infants with colic: growth and gastrointestinal tolerance. Eur J Clin Nutr. 2010;64:765–7.PubMedCrossRefGoogle Scholar
  88. 88.
    Di Pierro F, Donato G, Fomia F, et al. Preliminary pediatric clinical evaluation of the oral probiotic Streptococcus salivarius K12 in preventing recurrent pharyngitis and/or tonsillitis caused by Streptococcus pyogenes and recurrent acute otitis media. Int J Gen Med. 2012;5:991–7.PubMedCrossRefGoogle Scholar
  89. 89.
    Picaud JC, Chapalain V, Paineau D, et al. Incidence of infectious diseases in infants fed follow-on formula containing synbiotics: an observational study. Acta Paediatr. 2010;99:1695–700.PubMedCrossRefGoogle Scholar
  90. 90.
    Maldonado J, Cañabate F, Sempere L, et al. Human milk probiotic Lactobacillus fermentum CECT5716 reduces the incidence of gastrointestinal and upper respiratory tract infections in infants. J Pediatr Gastroenterol Nutr. 2012;54:55–61.PubMedCrossRefGoogle Scholar
  91. 91.
    Kukkonen K, Savilahti E, Haahtela T, et al. Long-term safety and impact on infection rates of postnatal probiotic and prebiotic (synbiotic) treatment: randomized, double-blind, placebo-controlled trial. Pediatrics. 2008;122:8–12.PubMedCrossRefGoogle Scholar
  92. 92.
    van Stuijvenberg M, Eisses AM, Grüber C, et al. Do prebiotics reduce the number of fever episodes in healthy children in their first year of life: a randomised controlled trial. Br J Nutr. 2011;106:1740–8.PubMedCrossRefGoogle Scholar
  93. 93.
    Popova M, Molimard P, Courau S, et al. Beneficial effects of probiotics in upper respiratory tract infections and their mechanical actions to antagonize pathogens. J Appl Microbiol. 2012;113:1305–18.PubMedCrossRefGoogle Scholar
  94. 94.
    Taipale T, Pienihäkkinen K, Isolauri E, et al. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr. 2011;105:409–16.PubMedCrossRefGoogle Scholar
  95. 95.
    Rautava S, Salminen S, Isolauri E. Specific probiotics in reducing the risk of acute infections in infancy – a randomised, double-blind, placebo-controlled study. Br J Nutr. 2009;101:1722–6.PubMedCrossRefGoogle Scholar
  96. 96.
    Skovbjerg S, Roos K, Holm SE, et al. Spray bacteriotherapy decreases middle ear fluid in children with secretory otitis media. Arch Dis Child. 2009;94:92–8.PubMedCrossRefGoogle Scholar
  97. 97.
    Hatakka K, Blomgren K, Pohjavuori S, et al. Treatment of acute otitis media with probiotics in otitis-prone children – a double-blind, placebo-controlled randomised study. Clin Nutr. 2007;26:314–21.PubMedCrossRefGoogle Scholar
  98. 98.
    Stecksén-Blicks C, Sjöström I, Twetman S. Effect of long-term consumption of milk supplemented with probiotic lactobacilli and fluoride on dental caries and general health in preschool children: a cluster-randomized study. Caries Res. 2009;43:374–81.PubMedCrossRefGoogle Scholar
  99. 99.
    Niittynen L, Pitkäranta A, Korpela R. Probiotics and otitis media in children. Int J Pediatr Otorhinolaryngol. 2012;76:465–70.PubMedCrossRefGoogle Scholar
  100. 100.
    Weichert S, Schroten H, Adam R. The role of prebiotics and probiotics in prevention and treatment of childhood infectious diseases. Pediat Infect Dis J. 2012;31:859–62.CrossRefGoogle Scholar
  101. 101.
    Sazawal S, Dhingra U, Hiremath G, et al. Prebiotic and probiotic fortified milk in prevention of morbidities among children: community-based, randomized, double-blind, controlled trial. PLoS One. 2010;5:e12164.PubMedCrossRefGoogle Scholar
  102. 102.
    Hao Q, Lu Z, Dong BR, et al. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2011;9:CD006895.PubMedGoogle Scholar
  103. 103.
    Salvini FJ, Riva E, Salvatici E, et al. A specific prebiotic mixture added to starting infant formula has long-lasting bifidogenic effects. J Nutr. 2011;141:1335–9.PubMedCrossRefGoogle Scholar
  104. 104.
    Stam J, van Stuijvenberg M, Garssen J, et al. A mixture of three prebiotics does not affect vaccine specific antibody responses in healthy term infants in the first year of life. Vaccine. 2011;29:7766–72.PubMedCrossRefGoogle Scholar
  105. 105.
    Hong P, Ninonuevo MR, Lee B, et al. Human milk oligosaccharides reduce HIV-1-gp120 binding to dendritic cell-specific ICAM3-grabbing non-integrin (DC-SIGN). Br J Nutr. 2009;101:482–6.PubMedCrossRefGoogle Scholar
  106. 106.
    Sanz-Penella JM, Frontela C, Ros G, et al. Application of bifidobacterial phytases in infant cereals: effect on phytate contents and mineral dialyzability. J Agric Food Chem. 2012;60:11787–892.PubMedCrossRefGoogle Scholar
  107. 107.
    Capozzi V, Russo P, Dueñas MT, et al. Lactic acid bacteria producing B-group vitamins: a great potential for functional cereals products. Appl Microbiol Biotechnol. 2012;96:1383–94.PubMedCrossRefGoogle Scholar
  108. 108.
    • Shanahan F. A commentary on the safety of probiotics. Gastroenterol Clin North Am. 2012;41:869–76. Are probiotics really safe?.PubMedCrossRefGoogle Scholar
  109. 109.
    Allen SJ, Jordan S, Storey M, et al. Dietary supplementation with lactobacilli and bifidobacteria is well tolerated and not associated with adverse events during late pregnancy and early infancy. J Nutr. 2010;140:483–8.PubMedCrossRefGoogle Scholar
  110. 110.
    Martín-Muñoz MF, Fortuni M, Caminoa M, et al. Anaphylactic reaction to probiotics. Cow's milk and hen's egg allergens in probiotic compounds. Pediatr Allergy Immunol. 2012;23:778–84.PubMedCrossRefGoogle Scholar
  111. 111.
    •• Dai M, Lu J, Wang Y, et al. In vitro development and transfer of resistance to chlortetracycline in Bacillus subtilis. J Microbiol. 2012;50:807–12. The danger of transfer of plasmid resistance with some probiotic strains.PubMedCrossRefGoogle Scholar
  112. 112.
    Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in Saccharomyces boulardii fungemia. Eur J Clin Microbiol Infect Dis. 2000;19:16–20.PubMedCrossRefGoogle Scholar
  113. 113.
    Venugopalan V, Shriner KA, Wong-Beringer A. Regulatory oversight and safety of probiotic use. Emerg Infect Dis. 2010;16:1661–5.PubMedCrossRefGoogle Scholar
  114. 114.
    Manzoni P, De Luca D, Stronati M, et al. Prevention of nosocomial infections in neonatal intensive care units. Am J Perinatol. 2013;30:81–8.PubMedCrossRefGoogle Scholar
  115. 115.
    Weichert S, Schroten H, Adam R. The role of prebiotics and probiotics in prevention and treatment of childhood infectious diseases. Pediatr Infect Dis J. 2012;31:856–62.CrossRefGoogle Scholar
  116. 116.
    Mugambi MN, Musekiwa A, Lombard M, et al. Synbiotics, probiotics or prebiotics in infant formula for full term infants: a systematic review. Nutr J. 2012;11:81.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Y. Vandenplas
    • 1
  • E. De Greef
    • 1
  • T. Devreker
    • 1
  • G. Veereman-Wauters
    • 1
  • B. Hauser
    • 1
  1. 1.Pediatric Gastroenterology, UZ BrusselVrije Universiteit BrusselBrusselsBelgium

Personalised recommendations